Syngene International : Analysts/Institutional Investor Meet/Con. Call Updates
December 28, 2022 at 11:42 am
Share
Ref: Syn/CS/SE/Reg 30/2022-23/Dec /10
Syngene International Limited
Biocon SEZ, Biocon Park, Plot No. 2 &
3, Bommasandra Industrial Area, IV
Phase, Jigani Link Road, Bengaluru
560 099, Karnataka, India
T +91 80 6891 8000
F +91 80 6775 8808
CIN: L85110KA1993PLC014937
December 26, 2022
www.syngeneintl.com
To,
To,
The Manager,
The Manager,
BSE Limited
National Stock Exchange of India Limited
Corporate Relationship Department
Corporate Communication Department
Dalal Street, Mumbai - 400 001
Bandra (EAST), Mumbai - 400 051
Scrip Code: 539268
Scrip Symbol: SYNGENE
Dear Sir/Madam,
Subject: Update on Conference Call for Analysts and Investors
Pursuant to regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in continuation to the intimation dated December 20,2022 (Ref: Syn/CS/SE/Reg 30/2022- 23/Dec/08) investor meeting with Carnelian Capital which was to be held on 27/12/2022 has been cancelled and rescheduled on 28/12/2022.
The above-mentioned information will also be available on the website of the Company www.syngeneintl.com.
Request to kindly take this intimation on record.
Thanking You,
Yours faithfully,
For SYNGENE INTERNATIONAL LIMITED
PRIYADARSHIN I MAHAPATRA
Digitally signed by PRIYADARSHINI MAHAPATRA DN: c=IN, o=Personal, pseudonym=bc2eb3d598e4b4695dfab584d8c4954317f2c9 b276b0ead69f4b6de415c5150d, 2.5.4.20=3b3032863a60d6cf503dc962d0b81de07d5cef262 29a00b5f723a1ef57ab0005, postalCode=751015, st=ODISHA, serialNumber=df67e39aa5435d22f718c22d0516d97afb120 8536f4f1860285e06c72d0c9992, cn=PRIYADARSHINI
MAHAPATRA
Date: 2022.12.26 20:01:24 +05'30'
Priyadarshini Mahapatra
Company Secretary and Compliance Officer
Attachments
Original Link
Original Document
Permalink
Disclaimer
Syngene International Ltd. published this content on 26 December 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 December 2022 11:20:08 UTC.
Syngene International Limited is an integrated research, development, and manufacturing services company. The Company is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide. Its services include drug discovery and development capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process research and development, current good manufacturing practice (cGMP) manufacturing, formulation, and analytical development, along with clinical development services. It offers SynVent, a therapeutic discovery and development platform for executing drug discovery projects. SynVent's portfolio covers modalities and therapeutic areas ranging from small molecule inhibitors to targeted protein stabilization. It serves the pharmaceutical, biotechnology, and specialty chemical sectors, among others. It operates multi-modal biologics manufacturing facility.